Curaleaf Registers 24M Shares for Hostile Aurora Takeover Bid
CURLF sits 71% above its 52-week low of $5.4.
Summary
Curaleaf registered 24 million shares to complete its hostile takeover of Aurora Cannabis, offering US$4.00 per share (45% premium) in cash and stock.
Key Events · M&A and Partnerships · CURLF
-
Hostile Takeover Bid Formalized
Curaleaf filed an F-80 registration statement to issue up to 24,021,022 subordinate voting shares for its hostile takeover of Aurora Cannabis, offering US$4.00 per share (45% premium to 30-day VWAP).
-
Exchange Ratio and Cap Price
Each Aurora share receives 0.3463 Curaleaf shares plus US$0.75 cash, subject to a US$5.00 cap price if Curaleaf's 20-day VWAP exceeds C$17.05.
-
Offer Conditions and Expiry
The offer expires December 1, 2026, and requires more than 50% of Aurora shares to be tendered (excluding Curaleaf-held shares) and at least 66⅔% on a fully-diluted basis.
-
Cash Funding from Balance Sheet
Curaleaf estimates US$48.6 million in cash consideration (US$52 million if all convertible securities are exercised), funded entirely from cash on hand with no financing condition.
Analysis · CURLF · Life Sciences
The F-80 registration statement filed by Curaleaf clears the way for issuing up to 24,021,022 subordinate voting shares in its hostile takeover of Aurora Cannabis. The offer values Aurora at US$4.00 per share — a 45% premium to the 30-day VWAP — with each Aurora share exchanged for 0.3463 Curaleaf shares plus US$0.75 cash, capped at US$5.00. Making the share consideration legally issuable is a critical step toward completing the bid. The offer expires December 1, 2026, and requires more than 50% of Aurora shares to be tendered. Curaleaf will fund the US$48.6 million cash portion from cash on hand. This filing formalizes the mechanics of a deal that would create the world's largest publicly traded cannabis company with a pro forma market cap exceeding US$3.0 billion.
At the time of this filing, CURLF was trading at $9.22 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $5.40 to $15.15. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.